NICE TAs

02/09/2019
TA497: Golimumab for treating non-radiographic axial spondyloarthritis: Evidence-based recommendations on golimumab (Simponi) for severe non-radiographic axial spondyloarthritis. This drug is for adults who have tried nonsteroidal anti-inflammatory drugs (NSAIDs), but they have not worked.

14/05/2019
TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C: NICE Guidance TA499 (Glecaprevir–pibrentasvir for treating chronic hepatitis C)

05/09/2019
TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C: Evidence-based recommendations on glecaprevir–pibrentasvir (Maviret) for treating chronic hepatitis C in adults.

02/09/2019
TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen: Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic (secondary) breast cancer in adults who have had only 1 course of chemotherapy.

10/02/2020

TA516: Cabozantinib for treating medullary thyroid cancer

Evidence-based recommendations on cabozantinib (Cometriq) for treating medullary thyroid cancer in adults.

The scope for this technology appraisal included vandetanib (Caprelsa). NICE’s recommendations on vandetanib are published separately.

10/02/2020

TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma

Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive Hodgkin lymphoma in adults.

This guidance is a Cancer Drugs Fund reconsideration of brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA446). This guidance replaces TA446.

15/05/2019
TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine: NICE guidance for lenvatinib (Lenvima) and sorafenib (Nexavar) for progressive, locally advanced or metastatic differentiated thyroid cancer in adults who have had radioactive iodine.

26/02/2020
TA550: Vandetanib for treating medullary thyroid cancer: Evidence-based recommendations on vandetanib (Caprelsa) for treating medullary thyroid cancer in adults.

15/05/2019
TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence.: Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of stage III melanoma with lymph node involvement in adults.

27/02/2020
TA586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib: Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for multiple myeloma after 1 treatment with bortezomib in adults.

02/09/2019
TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma: Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for previously untreated multiple myeloma in adults.

27/02/2020
TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion: Evidence-based recommendations on aflibercept (Eylea) for treating visual impairment caused by macular oedema after branch retinal vein occlusion.